Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: MYDLARCZYK
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/2

Tytuł oryginału: Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat.
Autorzy: Bełtowski Jerzy, Wójcicka Grażyna, Mydlarczyk Mariusz, Jamroz Anna
Źródło: Pol. J. Pharmacol. 2002: 54 (2) s.143-150, il., bibliogr. 49 poz.
Sygnatura GBL: 313,156

Hasła klasyfikacyjne GBL:
  • farmacja

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta
  • szczury

    Streszczenie angielskie: Statins (3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors), apart from lowering plasma cholesterol, modulate other processes involved in atherogenesis. Paraoxonase (PON), contained in plasma high density lipoproteins, protects plasma lipoproteins from oxidative damage and is a potentially atheroprotective enzyme. We investigated the effect of cervastatin on oxidant-antioxidant balance and plasma PON activity. The adult male Wistar rats received cervistatin at a dose of 0.03 or 0.3 mg/kg/day for 3 weeks. Then, plasma concentration of lipid peroxidation products, total antioxidant capacity and PON activity were assayed. Plasma level of lipid peroxidation products was unchanged in low-dose group but decreased significantly in animals receiving high dose of cervivastatin. In this group, the concentration of malonyldialdehyde and 4-hydroxydialkenals was reduced by 46.6 p.c. whereas the level of lipid hydroperoxides was lowered by 59.3 p.c. Total plasma antioxidant capacity increased in low-dose group by 22.3 p.c. and in high-dose group by 27.2 p.c. PON activity toward paraoxon decreased by 16.1 p.c. and 11.6 p.c. in low- and high-dose groups, respectively. The activity toward phenyl acetate, which better corresponds wuith enzyme concentration, declined by 74.2 p.c. and 78.4 p.c. following lower and higher dose treatment, respectively. PON/arylesterase ratio raised in cervastatin-treated rats (low dose: +227.4 p.c., high dose: +328.2 p.c.).Cerivastatin had no effect on total plasma cholesterol but significantly decreased triglyceride level by 34.6 p.c...

    2/2

    Tytuł oryginału: The effect of peroxisome proliferator-activated receptors ŕ (PPARŕ) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity.
    Autorzy: Bełtowski J[erzy], Wójcicka G., Mydlarczyk M., Jamroz A.
    Źródło: J. Physiol. Pharmacol. 2002: 53 (3) s.463-475, il., bibliogr. 52 poz.
    Sygnatura GBL: 302,092

    Hasła klasyfikacyjne GBL:
  • farmacja
  • kardiologia

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta
  • szczury
  • płeć męska

    Streszczenie angielskie: The aim of this study was to investigate the effect of peroxisome proliferator activated receptors ŕ agonist, fenofibrate, on the level of oxidative stress, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity in the rat. The adult male Wistar rats received fenofibrate for 7 days. The drug was added to food at concentrations 0.005 p.c., 0.05 p.c. and 0.5 p.c., which corresponded to doses of 3, 30 and 300 mg/kg/day, respectively. Fenofibrate treatment dose-dependently reduced plasma concentration of malonyldialdehyde and 4-hydroxydialkenals. The level of these lipid peroxidation products in animals treated with 0.005 p.c., 0.05 p.c. and 0.5 p.c. fenofibrate was lower than in control group by 52.8 p.c., 62.7 p.c. and 87.1 p.c. respectively. Lipid hydroperoxides in plasma decreased by 29.7 p.c., 23.4 p.c and 27.5 p.c. in these groups, respectively. The drug had no significant effect on total antioxidant capacity measured as ferric reducing ability of plasma (FRAP). Paraoxonhydrolyzing activity (PON) of plasma paraoxonase was 81.5 p.c. lower in animals receiving 0.05 p.c. fenofibrate and 69.2 p.c. lower in rats treated with 0.5 p.c. fenofibrate than in control. Phenyl acetate hydrolyzing aactivity (arylesterase, AE) was reduced by 15.2 p.c., 49.6 p.c. and 55.8 p.c. in rats receiving 0.005 p.c., 0.05 p.c. and 0.5 p.c. fenofibrate, respectively. PON/AE ratio decreased following 0.05 p.c. and 0.5 p.c. fenofibrate by 64.9 p.c. and 30.4 p.c. respectively. The drug had no significant effect on total plasma triyglycerides and cholesterol concentrations...

    stosując format: